These observations suggest that the TMEM97/σ2 receptor participates in breast tumor cell growth driven by estrogen receptor signaling and further renders tumor cells with an increased resistance toward endocrine therapeutics such as tamoxifen. The gene discussed is ESR1; the disease is neoplasm.